Study Finds Rifampicin‑Resistant TB Mutation Impairs Transcription Enzyme, Revealing New Weaknesses

Researchers identified a mutation in rifampicin‑resistant Mycobacterium tuberculosis. The genetic change slows the activity of the bacterium’s transcription enzyme. This reduced enzymatic speed creates physiological vulnerabilities in the pathogen. The findings suggest potential new targets for drug development. Scientists propose exploiting the weakened transcription process to enhance treatment efficacy. The study adds to understanding of resistance mechanisms in TB. Results may guide future clinical strategies against drug‑resistant strains. Further laboratory work is planned to validate therapeutic approaches.